Treatment with TMZ increases the binding of LNX1 to Numb and the ubiquitination of LNX1, thereby regulating Notch signaling through the LNX1–Numb–Notch1 axis, which further influences therapeutic resistance in GBM [131]. The gene discussed is LNX1; the disease is glioblastoma.